<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701142</url>
  </required_header>
  <id_info>
    <org_study_id>1470</org_study_id>
    <secondary_id>BI3023_2002</secondary_id>
    <secondary_id>2007-004612-31</secondary_id>
    <nct_id>NCT00701142</nct_id>
  </id_info>
  <brief_title>Haemocomplettan® P During Aortic Replacement</brief_title>
  <official_title>Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to show that administration of Haemocomplettan® P significantly
      reduces the amount of blood products needed during aortic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.</measure>
    <time_frame>From administration of Haemocomplettan® P until 24 hours later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that receive no allogeneic blood products (neither platelets, FFP, nor RBCs)</measure>
    <time_frame>From administration of Haemocomplettan® P until 24 hours later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in ICU</measure>
    <time_frame>Last suture of initial surgery to end of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>Last suture of initial surgery to end of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>45 days post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Haemocomplettan® P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion during aortic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemocomplettan® P</intervention_name>
    <description>Single intravenous infusion</description>
    <arm_group_label>Haemocomplettan® P</arm_group_label>
    <other_name>RiaSTAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Single intravenous infusion</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eighteen years of age or older

          -  Undergoing elective thoracoabdominal aortic replacement surgery (TAAA) or thoracic
             aortic replacement surgery (TAA)

          -  Understood and willingly given written informed consent (German language) to
             participate following an explanation of study background, restrictions, and procedures

          -  Experience clinically relevant bleeding of the microvasculature following removal of
             CPB during surgery

        Exclusion Criteria:

          -  Positive pregnancy test, pregnancy or lactation

          -  Women of child bearing age not using a medically approved method of contraception
             during the study

          -  Previous aortic replacement at the same aortic site (redo surgeries)

          -  Undergoing an emergency operation

          -  Proof or suspicion of a congenital or acquired coagulation disorder (e.g. VWD or via
             severe liver disease)

          -  Myocardial Infarction (MI) or apoplexy in the 2 months preceding study surgery

          -  ASA administration in the 3 days preceding study surgery, and a pathological (&lt;74.5 U)
             ASPI Multiplate® test immediately preceding surgery begin

          -  Clopidogrel administration in the 5 days preceding study surgery, and a pathological
             (&lt;31.1 U) ADP/PG Multiplate® test immediately preceding surgery begin

          -  Tirofiban administration in the 2 days preceding study surgery, and a pathological
             (&lt;94.1 U) TRAP Multiplate® test immediately preceding surgery begin

          -  Phenprocoumon administration in the 5 days preceding study surgery, and an INR &gt; 1.28
             immediately preceding surgery begin

          -  Participation in another clinical study in the 4 weeks preceding aortic replacement

          -  Sensitivity to any of the components of study medication, or to MPs with a similar
             chemical structure to any of the components of study medication

          -  Any indication that the restrictions or procedures of the study may not be adhered to
             (e.g. an uncooperative attitude)

          -  Any indication that the study restrictions, procedures, or consequences therein have
             not been considered or understood, such that informed consent cannot be convincingly
             given

          -  Multiple morbidities, with a notably constrained remaining length of life
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Rahe-Meyer, Dr. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abteilung Anästhesiologie, Carl-Neuberg-Strasse 1 / K5, 30177 Hannover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical School Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT00701142&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <results_reference>
    <citation>Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013 Jan;118(1):40-50. doi: 10.1097/ALN.0b013e3182715d4d. Erratum in: Anesthesiology. 2013 May;118(5):1244.</citation>
    <PMID>23249928</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>September 18, 2013</last_update_submitted>
  <last_update_submitted_qc>September 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

